医药稳健科研股策略:年化收益率（21.37%）
本策略精选医药生物行业中研发投入高、净利润快速增长、估值合理的优质股票。通过量化财务指标，筛选出具备持续成长潜力的标的，并定期轮动调仓，力求在医药行业中获取稳健收益。
概要
核心指标
- 累计收益率: 35.37%
- 年化收益率: 21.37%
- 基准收益率: 0.62%
- 阿尔法: 0.23
- 夏普比率: 0.72
- 最大回撤: 22.06%
源码
查看AI策略代码
绩效
持仓详情
|
当日收盘价 | 当日市值 | 浮动收益/浮动收益率
|
|||||
|---|---|---|---|---|---|---|---|
| 2025-04-28 | 千红制药(002550.SZ) | 6.051815033557 | 74500 | 3 | 5.99 | 446255 | -4605.22/-1.016% |
| 2025-04-28 | 浙江医药(600216.SH) | 13.995820231214 | 33400 | 28 | 13.39 | 447226 | -20234.4/-4.247% |
| 2025-04-28 | 九安医疗(002432.SZ) | 44.62137319331 | 11900 | 118 | 38.51 | 458269 | -72725.34/-13.505% |
| 2025-04-25 | 千红制药(002550.SZ) | 6.051815033557 | 74500 | 2 | 6.02 | 448490 | -2370.22/-0.51% |
| 2025-04-25 | 浙江医药(600216.SH) | 13.995820231214 | 33400 | 27 | 13.66 | 456244 | -11216.4/-2.369% |
| 2025-04-25 | 九安医疗(002432.SZ) | 44.62137319331 | 11900 | 117 | 39.14 | 465766 | -65228.34/-12.497% |
| 2025-04-24 | 千红制药(002550.SZ) | 6.051815033557 | 74500 | 1 | 6.21 | 462645 | 11784.78/2.685% |
| 2025-04-24 | 浙江医药(600216.SH) | 13.995820231214 | 33400 | 26 | 13.84 | 462256 | -5204.4/-1.089% |
| 2025-04-24 | 九安医疗(002432.SZ) | 44.62137319331 | 11900 | 116 | 38.38 | 456722 | -74272.34/-14.047% |
| 2025-04-24 | 辰欣药业(603367.SH) | 12.460360334165 | 0 | 151 | 13.64 | 0 | 33066.88/8.133% |
交易详情
| 2025-04-24 | 辰欣药业(603367.SH) | 卖 | -32115 | 13.51 | -433873.65 | ¥564.04 | 33709.18 |
| 2025-04-24 | 浙江医药(600216.SH) | 卖 | -1200 | 14.15 | -16980 | ¥22.07 | 185.02 |
| 2025-04-24 | 千红制药(002550.SZ) | 买 | 74500 | 6.05 | 450725 | ¥135.22 | 0 |
| 2025-04-17 | 九安医疗(002432.SZ) | 买 | 500 | 36.9 | 18450 | ¥5.54 | 0 |
| 2025-04-17 | 浙江医药(600216.SH) | 买 | 100 | 12.71 | 1271 | ¥5 | 0 |
| 2025-04-17 | 辰欣药业(603367.SH) | 买 | 100 | 13.68 | 1368 | ¥5 | 0 |
| 2025-04-10 | 九安医疗(002432.SZ) | 买 | 100 | 36.81 | 3681 | ¥5 | 0 |
| 2025-04-10 | 辰欣药业(603367.SH) | 卖 | -1700 | 13.5 | -22950 | ¥29.84 | 1774.13 |
| 2025-04-02 | 浙江医药(600216.SH) | 买 | 600 | 13.72 | 8232 | ¥5 | 0 |
| 2025-04-02 | 辰欣药业(603367.SH) | 卖 | -300 | 14.25 | -4275 | ¥9.28 | 538.08 |
